Extension to study of zoledronic acid in osteoporotic children

• Research type

  Research Study

• Full title

  A 1-year, multicenter, open-label extension to CZOL446H2337 to evaluate safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids for chronic inflammatory conditions.

• IRAS ID

  118039

• Contact name

  Nick Shaw

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2010-020399-41

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  This is an extension to the ongoing paediatric study in which children with glucocorticoid-induced osteoporosis are treated with zoledronic acid. Patients entering this study will already have received treatment for one year in the core study and this study aims to extend the treatment and observation of the safety and efficacy of this drug for a further year.

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  13/SC/0079

• Date of REC Opinion

  25 Mar 2013

• REC opinion

  Further Information Favourable Opinion